Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.54 |
| ▸ | LHCGR | P22888 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24419937 | 0.95 | HHAT (0.55) | HHATLHCGRMAPK1NPSR1HDAC8 | |
| SCHEMBL23948167 | 0.94 | HHAT (0.56) | HHATLHCGRMAPK1NPSR1HDAC8 | |
| SCHEMBL24419736 | 0.93 | HHAT (0.55) | HHATLHCGRMAPK1NPSR1HDAC8 | |
| SCHEMBL23947755 | 0.85 | HHAT (0.45) | HHATLHCGRMAPK1NPSR1HDAC8 | |
| SCHEMBL25050848 | 0.82 | HDAC8 (0.65) | HHATMAPK1NPSR1HDAC8 | |
| SCHEMBL25047674 | 0.78 | HDAC8 (0.58) | HHATMAPK1NPSR1HDAC8 | |
| SCHEMBL23947756 | 0.76 | HDAC8 (0.60) | HHATHDAC8 | |
| SCHEMBL24419737 | 0.76 | HDAC8 (0.58) | HHATHDAC8 | |
| SCHEMBL5439863 | 0.75 | HHAT (0.48) | HHATLHCGRMAPK1NPSR1 | |
| SCHEMBL1499097 | 0.75 | HHAT (0.48) | HHATLHCGRMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | HHAT 2179/4885LHCGR 3029/4885MAPK1 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.